73 related articles for article (PubMed ID: 3604838)
21. Changes of circulating immune complexes in the serum and CSF of patients with multiple sclerosis.
Cojocaru M; Cojocaru MI; Steriu O; Băldescu R
Rom J Intern Med; 1992; 30(1):51-6. PubMed ID: 1496259
[TBL] [Abstract][Full Text] [Related]
22. Decreased metastasis and improved survival with early thoracic radiotherapy and prophylactic cranial irradiation in combined-modality treatment of limited-stage small cell lung cancer.
Kamath SS; McCarley DL; Zlotecki RA
Radiat Oncol Investig; 1998; 6(5):226-32. PubMed ID: 9822169
[TBL] [Abstract][Full Text] [Related]
23. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
[TBL] [Abstract][Full Text] [Related]
24. Presence of circulating immune complexes in patients with chronic lymphocytic leukaemia. Correlations between clinical and immunological features.
Mozzana R; Baldini L; Neri A; Cortelezzi A; Radaelli F; Colajori E; Polli EE
Boll Ist Sieroter Milan; 1982; 61(4):324-9. PubMed ID: 6927220
[TBL] [Abstract][Full Text] [Related]
25. [The clinical course and treatment results of lung metastases from breast cancer].
Xu B; Zhou J; Zhou A
Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):274-6. PubMed ID: 11038757
[TBL] [Abstract][Full Text] [Related]
26. [Influence of antiplatelet drugs (AD) on the efectiveness of combined therapy of small cell lung cancer. Part II. Influence of treatment on time of remission and patients survival].
Ochmański W
Przegl Lek; 2008; 65(7-8):321-8. PubMed ID: 19004228
[TBL] [Abstract][Full Text] [Related]
27. Significance of circulating immune complexes in pulmonary tuberculosis.
Samuel AM; Ashtekar MD; Ganatra RD
Clin Exp Immunol; 1984 Nov; 58(2):317-24. PubMed ID: 6437714
[TBL] [Abstract][Full Text] [Related]
28. Breast conservation after neoadjuvant chemotherapy for stage II carcinoma of the breast.
Schwartz GF; Meltzer AJ; Lucarelli EA; Cantor JP; Curcillo PG
J Am Coll Surg; 2005 Sep; 201(3):327-34. PubMed ID: 16125064
[TBL] [Abstract][Full Text] [Related]
29. [Adjuvant chemotherapy following radical surgery for non-small cell lung cancer: a randomized study].
Xu G; Rong T; Lin P
Zhonghua Zhong Liu Za Zhi; 1998 May; 20(3):228-30. PubMed ID: 10921016
[TBL] [Abstract][Full Text] [Related]
30. [Circulating immune complex and complement (C3) in a course of pulmonary tuberculosis].
Dubaniewicz A; Sztaba-Kania M
Pol Merkur Lekarski; 2002 Jun; 12(72):491-5. PubMed ID: 12362668
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of circulating immune complexes and serum immunoglobulins in oral cancer patients--a follow up study.
Parveen S; Taneja N; Bathi RJ; Deka AC
Indian J Dent Res; 2010; 21(1):10-5. PubMed ID: 20427899
[TBL] [Abstract][Full Text] [Related]
32. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
Ardavanis A; Scorilas A; Tryfonopoulos D; Orphanos G; Missitzis I; Karamouzis M; Chrysochoou M; Sotiropoulou A; Arnogiannaki N; Ioannidis G; Pissakas G; Rigatos G
Oncologist; 2006 Jun; 11(6):563-73. PubMed ID: 16794236
[TBL] [Abstract][Full Text] [Related]
33. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
Franciosi V; Cocconi G; Michiara M; Di Costanzo F; Fosser V; Tonato M; Carlini P; Boni C; Di Sarra S
Cancer; 1999 Apr; 85(7):1599-605. PubMed ID: 10193952
[TBL] [Abstract][Full Text] [Related]
34. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy in stage III breast cancer.
Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD
Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927
[TBL] [Abstract][Full Text] [Related]
36. Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes.
Kümmel S; Eggemann H; Lüftner D; Thomas A; Jeschke S; Zerfel N; Heilmann V; Emons G; Zeiser T; Ulm K; Kobl M; Korlach S; Schmid P; Sehouli J; Elling D; Blohmer JU
Anticancer Res; 2006; 26(2C):1719-26. PubMed ID: 16617567
[TBL] [Abstract][Full Text] [Related]
37. [Circulating immune complex and cancer in the digestive system].
Wang YM
Zhonghua Zhong Liu Za Zhi; 1985 Nov; 7(6):445-7. PubMed ID: 3836848
[TBL] [Abstract][Full Text] [Related]
38. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
39. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
Langer CJ; Moughan J; Movsas B; Komaki R; Ettinger D; Owen J; Wilson JF
Lung Cancer; 2005 Apr; 48(1):93-102. PubMed ID: 15777975
[TBL] [Abstract][Full Text] [Related]
40. Influence of splenectomy on the levels of circulating immune complexes (CIC) in Hodgkin's disease (HD).
Nerurkar AV; Advani SH; Gothoskar BP
Neoplasma; 1987; 34(1):89-93. PubMed ID: 3561608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
